This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...

Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...

A new study of nerve cells affected by Huntington’s disease (HD) reveals that the disease-causing gene slowly expands over ...

Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...